#USA #Cambridge #MetaVia #Obesity Treatment #DA-1726

MetaVia's Phase 1 Clinical trial of DA-1726: Advancements in Obesity Treatment

MetaVia Inc., a biotechnology firm specializing in cardiometabolic diseases, has recently released promising findings from its Phase 1 multiple ascending dose (MAD) study of DA-1726. This innovative treatment is a dual agonist that targets both glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), showcasing its potential as a best-in-class solution for obesity management.

Key Findings of the Study

The study, conducted over a 28-day period with 36 participants, indicated a significant dose-dependent reduction in body weight among subjects receiving doses from 8 mg to 32 mg. The results highlighted that higher doses are correlated with greater weight loss and an improved body mass index (BMI). Specifically, weight loss was substantial, reaching an average maximum of -6.3% by day 26 of treatment, alongside a notable decrease in waist circumference. Comparatively, the placebo group showed significantly lesser effects, underscoring the efficacy of DA-1726.

One of the highlighted aspects of DA-1726 is its safety profile. The administration of doses up to 32 mg did not correlate with any adverse cardiovascular effects, as evidenced by measurements of heart rate and QTc interval, essential indicators of cardiac health. In fact, most subjects demonstrated slight decreases in heart rate, contrary to the typical concerns associated with dual receptor agonists. This is particularly noteworthy given the historical discontinuation of similar treatments due to safety issues such as abnormal heart rate increases.

Implications for Future Trials

MetaVia’s CEO, Hyung Heon Kim, asserted the potential of DA-1726 as a revolutionary treatment for obesity. The innovative drug’s mechanism of action—activating both GLP-1 and glucagon pathways—could help mitigate the high rates of discontinuation (20% to 70%) often seen with traditional GLP-1 therapies.

Plans for subsequent phases of the clinical trial are underway to include additional cohorts that will investigate the maximum tolerated dose. These studies aim to validate the observed benefits and expand the understanding of DA-1726’s profile, particularly its effects on metabolic parameters and overall tolerability in a diverse participant group.

Mechanism of Action and Benefits

DA-1726 operates as a dual agonist, simultaneously targeting GLP-1 and glucagon receptors, which enhances weight loss through appetite suppression and increased energy expenditure. Preclinical studies suggest that DA-1726 outperforms existing treatments such as semaglutide and cotadutide, while also preserving lean muscle mass—a crucial factor in weight management strategies.

In summary, DA-1726 not only demonstrates significant potential as a weight loss therapy but also counters common concerns regarding cardiovascular safety, making it a promising candidate in the fight against obesity. The next steps in its development, including the Phase 1 Part 3 study, are eagerly anticipated not only by the medical community but also by numerous patients who struggle with weight management.

For ongoing updates about DA-1726 and related clinical trials, readers can visit clinicaltrials.gov under the identifier NCT06252220. The implications of successful outcomes from these studies could set new standards for obesity treatment worldwide.